FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.

Sector

Healthcare

Industry

Medical - Care Facilities

CEO

Baran, Jakub

Employees

771

Website

www.famicord.com

IPO Date

2007-03-27

Headquarters

Perlickstrasse 5, Leipzig, Saxony, 04103, Germany

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

FamiCord V3V

FamiCord Earnings Call Summary

FamiCord Earnings

Transcripts

Events

About FamiCord AG

FamiCord
V3V